Moderna, Inc. - Common Stock (MRNA)

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.

The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

The new Health Secretary reportedly recommended Moderna's RSV vaccine for a broader group of adults.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.

Shares have long struggled, but things could be looking up for Moderna stock in the face of new flu shot results.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate.

The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts.

RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.'s overhaul of the CDC's key vaccine advisory panel threatens public health and undermines decades of immunization progress, potentially impacting pharmaceutical companies and healthcare markets.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index.

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

The company plans to make mRESVIA available for both younger and older adults in the U.S. ahead of the 2025-2026 respiratory virus season.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8.4%. This drawdown was discouraging since the S&P 500 held its ground.